Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia
Richard R. Furman(Cornell University), Susan O’Brien(University of California, Irvine), Andrew R. Pettitt(University of Liverpool), Nicole Lamanna(Memorial Sloan Kettering Cancer Center), Jeff P. Sharman(Willamette Valley Cancer Institute and Research Center), Steven Coutré(Georgetown University), Paula Cramer(Memorial Sloan Kettering Cancer Center), Stephan Stilgenbauer(Universität Ulm), Thomas J. Kipps(University of California San Diego), John M. Pagel(University of Washington), Roger Dansey(Memorial Sloan Kettering Cancer Center), Maria Aiello(Memorial Sloan Kettering Cancer Center), Peter Hillmen(Leeds Teaching Hospitals NHS Trust), Thomas J. Ervin(Bayfront Medical Center), Andrew D. Zelenetz(Memorial Sloan Kettering Cancer Center), Herbert Eradat(University of Colorado Cancer Center), Jacqueline C. Barrientos(Mount Sinai Medical Center), Michael Hallek(Integrated Oncology (United States)), Shuo Ma(Nantong University), Bruce D. Cheson(Center for Cancer and Blood Disorders), Paolo Ghia(Vita-Salute San Raffaele University), Thomas M. Jahn(Memorial Sloan Kettering Cancer Center), Daniel Li(Memorial Sloan Kettering Cancer Center), Dave M. Johnson(Memorial Sloan Kettering Cancer Center), Ian W. Flinn(Tennessee Oncology), Langdon L. Miller(Gilead Sciences (United States)), Bertrand Coiffier(Unknown)
Cited by 1,684
Related Papers
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
|New England Journal of Medicine|2013|6.6k
Irinotecan plus Fluorouracil and Leucovorin for Metastatic Colorectal Cancer
|New England Journal of Medicine|2000|3k
Revised Recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia
|Journal of Clinical Oncology|2003|2.7k
Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma
|New England Journal of Medicine|2018|2.3k